Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $17

Citizens analyst Silvan Turkcan has maintained a Market Outperform rating on Relay Therapeutics (NASDAQ: RLAY) and increased the price target from $15 to $17. This adjustment reflects a positive outlook for the company's performance in the market.